Form 4: Immunome Inc. Executive Acquires 190,000 Stock Options

Immunome Inc.'s EVP, Operations & CFO, Max Rosett, acquired 190,000 stock options on August 9, 2024, at an exercise price of $12.92.

Summary

• This is a Form 4 filing, indicating a change in beneficial ownership of securities.
• Max Rosett, EVP, Operations & CFO of Immunome Inc. [IMNM], acquired 190,000 stock options on August 9, 2024.
• The exercise price of these options is $12.92.
• 25% of the shares subject to the options vest on August 9, 2025, and the remaining shares vest monthly over the following 36 months.
• The options expire on August 8, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of options by an executive could be interpreted as a slightly positive signal, but it's not definitive.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in the holdings of a company insider, which is common practice.

Stakeholder Impact

• Shareholders may view the executive's acquisition of stock options as a sign of confidence in the company's future prospects.

Key Dates